Cargando…

A Review of Romiplostim Mechanism of Action and Clinical Applicability

Thrombocytopenia results from a variety of conditions, including radiation, chemotherapy, autoimmune disease, bone marrow disorders, pathologic conditions associated with surgical procedures, hematopoietic stem cell transplant (HSCT), and hematologic disorders associated with severe aplastic anemia....

Descripción completa

Detalles Bibliográficos
Autores principales:	Bussel, James B, Soff, Gerald, Balduzzi, Adriana, Cooper, Nichola, Lawrence, Tatiana, Semple, John W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165097/ https://www.ncbi.nlm.nih.gov/pubmed/34079225 http://dx.doi.org/10.2147/DDDT.S299591

Ejemplares similares

Romiplostim use in pregnant women with immune thrombocytopenia
por: Bussel, James B., et al.
Publicado: (2022)

A single-arm, long-term efficacy and safety study of subcutaneous romiplostim in children with immune thrombocytopenia
por: Grainger, John, et al.
Publicado: (2022)

Romiplostim in children with newly diagnosed or persistent primary immune thrombocytopenia
por: Grainger, John D., et al.
Publicado: (2021)

Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia
por: Soff, Gerald A., et al.
Publicado: (2019)

Romiplostim for chemotherapy‐induced thrombocytopenia: Efficacy and safety of extended use
por: Wilkins, Cy R., et al.
Publicado: (2022)

Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia
por: Tarantino, Michael D., et al.
Publicado: (2019)

Assessment of romiplostim immunogenicity in pediatric patients in clinical trials and in a global postmarketing registry
por: Bowers, Charles, et al.
Publicado: (2021)

Long-Term Use of the Thrombopoietin-Mimetic Romiplostim in Children With Severe Chronic Immune Thrombocytopenia (ITP)
por: Bussel, James B, et al.
Publicado: (2015)

Efficacy and Safety of Biosimilar Romiplostim Versus Innovator Romiplostim in Patients with Chronic Immune Thrombocytopenia
por: Chandrakala, S., et al.
Publicado: (2022)

Open-label pilot study of romiplostim for thrombocytopenia after autologous hematopoietic cell transplantation
por: Scordo, Michael, et al.
Publicado: (2022)

Correction to: Efficacy and Safety of Biosimilar Romiplostim Versus Innovator Romiplostim in Patients with Chronic Immune Thrombocytopenia
por: Chandrakala, S., et al.
Publicado: (2023)

PB2612: UNITED KINGDOM RETROSPECTIVE OBSERVATIONAL STUDY OF ROMIPLOSTIM AND OTHER TREATMENTS IN EARLY IMMUNE THROMBOCYTOPENIA
por: Mcdonald, Vickie, et al.
Publicado: (2023)

Assessment of immunogenicity of romiplostim in clinical studies with ITP subjects
por: Jawa, Vibha, et al.
Publicado: (2010)

Romiplostim as a treatment for immune thrombocytopenia: a review
por: Chalmers, Sarah, et al.
Publicado: (2015)

The role of romiplostim for pediatric patients with immune thrombocytopenia
por: Al-Samkari, Hanny, et al.
Publicado: (2020)

Quality by Design in Downstream Process Development of Romiplostim
por: Pouri, Saeedeh, et al.
Publicado: (2022)

A randomized, double‐blind, comparative study of the pharmacodynamics and pharmacokinetics of GP40141 (romiplostim biosimilar) and reference romiplostim in healthy male volunteers
por: Makarenko, Igor, et al.
Publicado: (2023)

Romiplostim as early treatment of immune thrombocytopenia with severe immunodeficiency
por: Palandri, Francesca, et al.
Publicado: (2012)

Role of romiplostim in splenectomized and nonsplenectomized patients with immune thrombocytopenia
por: Perdomo, Jose
Publicado: (2016)

Thrombopoietin mutation in congenital amegakaryocytic thrombocytopenia treatable with romiplostim
por: Pecci, Alessandro, et al.
Publicado: (2017)

Efficacy and quality of life of Romiplostim in adults and children with immune thrombocytopenia: A review
por: He, Xin, et al.
Publicado: (2022)

Safety and efficacy of romiplostim in children and adolescents with Immune thrombocytopenia: A systematic review
por: de Oliveira, Fernanda Lubiana, et al.
Publicado: (2023)

Recovery of Bone Marrow Function in VEXAS Syndrome-potential Role for Romiplostim
por: Al-Hakim, Adam, et al.
Publicado: (2023)

Myelofibrosis Associated with Romiplostim Treatment in a Patient with Immune Thrombocytopenia
por: Gonzalez, Maria Fernanda, et al.
Publicado: (2012)

Cost Effectiveness of Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in Ireland
por: Lee, Dawn, et al.
Publicado: (2013)

Romiplostim for the Emergency Management of Severe Immune Thrombocytopenia with Intracerebral Hemorrhage
por: Gellens, Romain, et al.
Publicado: (2018)

Expression, purification and biological activity assessment of romiplostim biosimilar peptibody
por: Fayaz, Shima, et al.
Publicado: (2016)

Long-term safety and efficacy of romiplostim for treatment of immune thrombocytopenia
por: Vishnu, Prakash, et al.
Publicado: (2016)

Treatment of 5 dogs with immune-mediated thrombocytopenia using Romiplostim
por: Kohn, Barbara, et al.
Publicado: (2016)

Romiplostim and Eltrombopag in Immune Thrombocytopenia as a Second-Line Treatment
por: Bidika, Erjola, et al.
Publicado: (2020)

Assessment of romiplostim immunogenicity in adult patients in clinical trials and in a global postmarketing registry
por: Mytych, Daniel T., et al.
Publicado: (2020)

Safety and Efficacy of Eltrombopag and Romiplostim in Myelodysplastic Syndromes: A Systematic Review and Meta-Analysis
por: Meng, Fanqiao, et al.
Publicado: (2020)

Reduced corticosteroid use in adult patients with primary immune thrombocytopenia receiving romiplostim
por: Michel, Marc, et al.
Publicado: (2011)

Erratum to: Cost Effectiveness of Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in Ireland
por: Lee, Dawn, et al.
Publicado: (2013)

Erratum to: treatment of 5 dogs with immune-mediated thrombocytopenia using romiplostim
por: Kohn, Barbara, et al.
Publicado: (2016)

Successful Percutaneous Nephrolithotomy in Patients with Immune-Mediated Thrombocytopenia Treated with Romiplostim
por: McCall, Andrew N., et al.
Publicado: (2016)

Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia
por: Cines, Douglas B., et al.
Publicado: (2017)

Romiplostim for the Treatment of Immune Thrombocytopenia: Spotlight on Patient Acceptability and Ease of Use
por: Gilbert, Megan M, et al.
Publicado: (2020)

Azathioprine/immune-globulin/methylprednisolone/romiplostim: Lack of efficacy: case report
Publicado: (2021)

Thrombopoietin receptor agonists: ten years later
por: Ghanima, Waleed, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6niqbfpsafls4vc12ehvhn7vib